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Abstract
Background—Race and sex differences in silent myocardial infarction (SMI) are not well-
established.
Methods and Results—The analysis included 9,498 participants from the ARIC study who 
were free of cardiovascular disease at baseline (visit-1; 1987–1989). Incident SMI was defined as 
ECG-evidence of MI without clinically documented MI (CMI) after the baseline until ARIC 
visit-4 (1996–1998). Coronary heart disease (CHD) and all-cause deaths were ascertained starting 
from ARIC visit-4 until 2010. During a median follow-up of 8.9 years, 317 (3.3%) participants 
developed SMI while 386 (4.1%) developed CMI. The incidence rates of both SMI and CMI were 
higher in men (5.08 and 7.96 per 1000-person years, respectively) than in women (2.93 and 2.25 
per 1000-person years, respectively); p-value <.0001 for both. Blacks had non-significantly higher 
rate of SMI than whites (4.45 vs. 3.69 per 1000-person years; p-value=0.217) but whites had 
higher rate of CMI than blacks (5.04 vs. 3.24 per 1000-person years; p-value=0.002). SMI and 
CMI (vs. no MI) were associated with increased risk of CHD death (HR(95%CI): 3.06(1.88–4.99) 
and 4.74(3.26–6.90), respectively) and all-cause mortality (HR(95%CI):1.34(1.09–1.65) and 
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1.55(1.30–1.85), respectively). However, SMI and CMI were associated with increased mortality 
among both men and women, with potentially greater increased risk among women (interaction p-
value= 0.089 and 0.051, respectively). No significant interactions by race were detected.
Conclusions—SMI represents over 45% of incident MIs and is associated with poor prognosis. 
Race and sex differences in the incidence and prognostic significance of SMI exist which may 
warrant considering SMI in personalized assessment of CHD risk.
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INTRODUCTION
About 635,000 new cases of coronary heart disease (CHD) occur annually in the United 
States, with an additional 155,000 incidentally discovered asymptomatic silent MIs (SMI).
1 
SMI, defined as the presence of pathological Q waves in the absence of a history of typical 
cardiac symptoms, is one of the important cardiac abnormalities that can be reasonably 
detected through electrocardiogram (ECG) screening.
2, 3
Given that SMI is characterized by no or mild symptoms, those patients are deprived from 
medical treatments that could prevent subsequent adverse outcomes, including a second MI 
or even death.
4
 This underscores the importance of detection of SMI in clinical practice. In 
clinical trials evaluating interventions to prevent or treat CHD, detection of unrecognized MI 
as a clinical end point has the potential to increase statistical power and allowing decreased 
sample sizes or reduced length of follow-up, cost, and potential harm from exposure.
4
The reported incidence of SMI ranges from 22% to 60% of the total MI incidence, and the 
prognosis of these SMIs has been shown to be similar to, or worse than, clinically 
recognized MI 
4–27. However, the current understanding of the epidemiology of SMI is 
based primarily on studies in white populations of European ancestry,
8, 11–15, 18 or on 
studies with limited representation of both sexes.
9, 10, 16, 18, 21, 23 The lack of race and sex 
diversity in these studies is occasionally complicated by small sample size as well.
7, 28
The aim of this study was to examine the race and sex differences in the incidence and 
prognostic significance of SMI vs. MI with clinical manifestations (CMI) in the 




The ARIC study was designed to investigate the causes of atherosclerosis and its clinical 
outcomes, as well as variation in cardiovascular risk factors, medical care, and disease by 
race and sex.
29
 From 1987 to 1989 (ARIC study baseline), 15 792 adults (55.2% women; 
age, 45–64 years) from 4 US communities (Washington County, Maryland; suburbs of 
Minneapolis, Minnesota; Jackson, Mississippi; and Forsyth County, North Carolina) were 
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enrolled and underwent a phone interview and clinic visit. Additional examinations were 
conducted in 1990–1992 (visit 2), 1993–1995 (visit 3), 1996–1998 (visit 4), and 2011–2013 
(visit 5). Participants were mostly white in the Washington County and Minneapolis sites, 
exclusively black in Jackson, and a mix of both in Forsyth County. The study was approved 
by each study site’s institutional review board. All participants provided written informed 
consent.
For the purpose of this analysis, we included all ARIC participants with good quality and 
complete ECG data at visits 1 to 4 as well as outcome events after visit 4. We excluded the 
follwing partcipants: 47 with reported race other than African-American or white, 136 with 
poor quality ECG, 3,775 with missing ECG in any of the ARIC first 4 visits (including 871 
who died before visit 4), 429 with ECG diagnosis of bundle branch block, external 
pacemaker or Wolff-Parkinson-White pattern, and 201 with missing one or more of baseline 
cardiovascular disease (CVD) risk factors. We also excluded 1,706 participants with history 
of CVD at baseline which was defined as the presence of ECG evidence of MI, or a self-
reported history of physician-diagnosed MI, coronary artery bypass surgery, coronary 
angioplasty, heart failure, or stroke. After all exclusions (n=6,294), 9,498 remained and were 
included in the analysis.
Silent MI
Incident SMI was defined as ECG evidence of new MI at ARIC visit 2, visit 3 or visit 4 that 
was not present at the baseline visit (visit 1) in the absence of documented CMI. Participants 
with both SMI and CMI between ARIC visit 1 and visit 4 were considered as having CMI. 
Identical electrocardiographs (MAC PC, Marquette Electronics Inc., Milwaukee, Wisconsin) 
were used at all clinical sites, and resting 10-second standard simultaneous 12-lead ECGs 
were recorded in all participants using strictly standardized procedures. All ECGs were 
processed in a central ECG laboratory (initially at Dalhousie University, Halifax, Nova 
Scotia, Canada and later at the EPICARE Center, Wake Forest School of Medicine, 
Winston-Salem, North Carolina, USA), where all ECGs were visually inspected for 
technical errors and quality. ECG evidence of MI was defined by new appearance of 
Minnesota Code ECG Classifications as a major Q/QS wave abnormality (MC 1.1 or MC 
1.2), or minor Q/QS waves abnormality (MC 1.3) plus major ST-T abnormality (MC 4.1, 
MC 4.2, MC 5.1 or MC 5.2).
30, 31 Traditional serial change comparisons
30
 were not used.
CHD death and all-cause mortality
CHD death and all-cause mortality were ascertained after ARIC visit 4 (1996–1998) through 
December 31, 2010 from death certificates. Deaths and hospitalization events were 
ascertained in each clinical center during an annual follow-up phone interview or through 
review of community hospital discharge indexes. Incident CHD events included definite or 
probable hospitalized MI (clinical myocardial infarction, i.e. CMI in this analysis) or 
definite CHD death. All CHD events classification and specific criteria including the 
adjudication process have been previously described.
32–34 CMI was based on physician 
review and adjudication of chest pain, cardiac biomarkers/enzymes from hospitalizations, 
ECG evidence including a new pathological Q wave, CHD history, the underlying cause of 
death from death certificates, and other associated information. All eligible hospitalized 
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events were classified as either definite, probable, suspect, or no MI. Definite or probable MI 
was combined to define a clinically manifest MI (CMI) in this analysis. The definite 
hospitalized CMI met one or more of the following criteria: 1) Evolving diagnostic ECG 
pattern; 2) Diagnostic ECG pattern and abnormal enzymes; 3) Cardiac pain and abnormal 
enzymes plus evolving ST-T pattern or equivocal ECG pattern. The probable hospitalized 
MI met one or more of the following criteria in the absence of sufficient evidence for 
definite hospitalized MI: 1) Cardiac pain and abnormal enzymes; 2) Cardiac pain and 
equivocal enzymes and either evolving ST-T pattern or diagnostic ECG pattern. 3) Abnormal 
enzymes and evolving ST-T pattern. Criteria for each of these diagnostic elements in the 




Baseline age, sex, race, education level, income, and smoking status were determined by 
self-report. Body mass index at baseline was calculated as weight in kilograms divided by 
height in meters squared. Blood samples were obtained after an 8-hour fasting period. 
Baseline diabetes mellitus was defined as a fasting glucose level ≥126 mg/dL (or nonfasting 
glucose ≥200 mg/dL), a self-reported physician diagnosis of diabetes mellitus, or the use of 
diabetes medications. Baseline hypertension was defined as systolic blood pressure ≥140 
mm Hg, diastolic blood pressure ≥90 mm Hg, or the use of blood pressure–lowering 
medications. At each study visit, medication history was obtained by self-report of 
medication intake during last 2 weeks and by reviewing medications brought by the 
participants to their visits. Each medication was coded by trained and certified interviewers 
with the use of a computerized medication classification system. Prevalent stroke and 
peripheral arterial disease were identified by self-reported history of a previous physician 
diagnosis. Prevalent heart failure was identified by the Gothenburg criteria or self-reported 
history of heart failure medication use in the past 2 weeks.
Statistical methods
Frequency distributions of the variables used in analyses were first inspected to rule out 
anomalies and outliers. Descriptive statistics were used to determine mean values, standard 
deviations, and percentile distributions for continuous variables, and frequencies and 
percentages for categorical variables.
During the period from visit 1 to visit 4, incidence rates of SMI and CMI were calculated 
per 1000 person-years and compared in all ARIC participants as well as stratified by age, 
sex and race/ethnicity.
Cox proportional hazards analysis was used to examine the associations of SMI and CMI 
(vs. no MI) occurring from visit 1 to visit 4 with CHD death and all-cause mortality 
occurring after visit 4. The follow up time included the time elapsed between the 
identification of SMI or CMI plus the time from visit 4 to the event. Non-CHD deaths were 
treated as censored. Models were incrementally adjusted as follows: Model 1 adjusted for 
baseline demographics (age, sex and race), and Model 2 adjusted for variables in Model 1 
plus study field center, body mass index, income, education, smoking status, systolic blood 
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pressure, blood pressure lowering medications, diabetes mellitus, ratio of total cholesterol/
high density lipoprotein cholesterol, use of cholesterol lowering medications, use of aspirin, 
family history of CHD and serum creatinine (all variables measured at baseline). 
Interactions by sex and race were examined in Model 2. We examined the assumption of 
proportional hazards by computation of Schoenfeld residuals and inspection of log (−log 
[survival function]) curves, and they were met.
All analyses were performed with SAS version 9.3 (SAS Institute Inc., Cary, North 
Carolina). A 2-sided p <0.05 was considered significant. However, because the interactions 
tests were used for only screening for effect modification (interactions) by sex and race and 
not testing a hypothesized effect modification, we used a more relaxed p-value of 0.10 to 
define significance to detect interaction.
35
RESULTS
This analysis included 9,498 participants (age at baseline 54.0 (± 5.7) years, 56.9% women, 
and 20.3% African American). From baseline through the 4th ARIC visit, 317 participants 
developed SMI while 386 developed CMI. Table 1 shows the baseline characteristics of the 
study participants stratified by MI status.
Table 2 shows the incidence rate (per 1000 person-years) of SMI and CMI, overall and 
stratified by sex and race. Overall, the incidence rate of CMI was slightly higher than SMI. 
However, sex and race differences in the incidence of SMI and CMI were observed. The 
incidence rates of both SMI and CMI were higher in men compared to women (p-value <.
0001). On the other hand, blacks had non-significantly higher rate of SMI than whites (p-
value= 0.217) but white had higher rate of CMI than blacks (p-value=0.002). Figure 1 shows 
the incidence rates of SMI and CMI in white men, black men, white women and black 
women. As shown, the incidence rate of SMI was higher than CMI in black women, which 
is the opposite of what is observed in white men in whom CMI was more common than 
SMI. On the other hand, the incidence rates of SMI were comparable to those of CMI in 
white women and black men. During a median follow up of 13.2 years follow-up, 1,833 all-
cause mortality cases were detected of which 189 were CHD deaths. Figure 2 and Figure 3 
show the event (CHD death and all-cause mortality, respectively) -free survival curves by MI 
status (no MI, SMI and CMI). In multivariable adjusted Cox proportional hazards analysis, 
both SMI and CMI (compared to no MI) were associated with increased risk of CHD death 
(Table 3) and all-cause mortality (Table 4). However, SMI and CMI were associated with 
increased risk of mortality among both men and women, with potentially greater increased 
risk among women (interaction p-value=0.089 and 0.051, respectively). No significant 
interaction by race was detected.
DISCUSSION
In this analysis from the ARIC study, one of the largest community-based biracial cohort 
studies in the US, we examined the sex and racial differences in the incidence and 
prognostic significance of silent vs. clinically-manifested MI. The three key findings are: 1) 
SMI is common; about 45% of the MIs are silent; 2) Both SMI and CMI are associated with 
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poor prognosis with CMI showing slightly stronger association with risk of death than SMI; 
3) There are race and sex differences in the incidence and prognostic significance of SMI. 
These findings highlights the importance of detection of SMI, and the potential impact of 
such detection on personalized prevention of CHD that takes into account race and sex. This 
is further underscored by the known sex and race disparity in CHD incidence and 
prognosis,
36
 and the fact that those with SMI are deprived from medical attention compared 
to those with CMI.
Several previous studies have examined the prevalence, incidence and prognostic 
significance of SMI.
4–26 In literature reviews by Pride et al,
4
 and by Sheifer et al,
37
 SMI 
constituted up to 44% of the total MIs, and carried a prognosis that was as poor as that for 
CMIs. The prevalence and incidence of SMI differed, however, from one study to another. In 
the Cardiovascular Health Study (CHS), which is a predominantly white population of 
elderly aged 65 years and older, SMI accounted for 22% of the prevalent MIs.
19
 In a similar 
cohort of elderly patients aged >75 years, the Bronx Aging Study, SMIs represented 44% of 
the total MIs.
17
 On the other hand, in the Heart and Estrogen/progestin Replacement Study 
Trial, which included only women, SMI constituted only 4% of the total MI,
38
 which is 
much lower than the Reykjavik Study in Women in which SMIs represented 33% of the total 
MIs.
10
 Similarly, different studies showed different prognosis of SMI, with some reporting 
similar or poorer prognosis
17, 26 and others showing better prognosis with SMI compared to 
CMI.
7, 39
Differences in the incidence and prognostic significance among different studies could be 
explained by differences in the population studied (e.g. distribution of age, race and sex) and 
the method by which SMI is detected (e.g. Q wave in the ECG, myocardial scar in the 
cardiac magnetic resonance imaging, or areas of akinesia in the echocardiography). Even 
within studies that used ECG to define silent MI there are differences, some used serial 
Q/ST/T changes
26
 and others used MI at each point of time as our study. Regardless of these 
differences, the overall incidence and prognostic significance of SMI in these studies 
generally accord with our results. However, none of these studies had the large sample size 
or the ethnically diverse community-based population with good representation of both 
sexes as our study. Hence, the race and sex differences in the incidence and prognostic 
significance of SMI were not appropriately examined in previous studies. Therefore, our 
results expand upon the previous studies and also extend our previous ARIC report on SMI 
that examined the incidence but not the prognostic significance of these MIs.
40
Our observations of the race and sex differences in the incidence and prognostic significance 
of SMI adds to the accumulating evidence of the sex and racial differences in CVD 
outcomes and the potential differences in the impact of risk factors among sexes and races. 
Because we adjusted for several potential confounders, it is less likely that our observed sex 
and racial differences were confounded by differences in MI-associated morbidities. Future 
investigation should assess whether genetic background, emerging risk factors, access to 
health care, awareness, and adherence to medications contribute to sex and racial 
differences.
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Our results should be read in the context of certain limitations. Our analyses included only 
whites and blacks, and hence our results may not be generalizable to other races/ethnicities. 
Although we adjusted for several potential confounders in the models examining the 
association between SMI and CMI with outcomes, residual confounding remains a 
possibility as all similar studies. Q-waves often disappear after MI, and hence the SMI 
incidence in our study might be underestimated given the time between visits. Also, the 
increasing sensitivity of troponin in the past decade probably have yielded more CMI, and 
subsequently less SMI in the later stages of ARIC compared to before. Although this should 
not impact the race and sex differences, it may impact the trend of SMI over time. Also, 
there were no significant changes in the sensitivity of troponin before 1998, the date our 
ascertainment of silent MI ended. Despite these limitations, our study was able to document 
the race and sex differences in the incidence and prognostic significance of SMI and 
compare the results to CMI in a large, well-designed prospective cohort study with long term 
follow-up; the ARIC study. Other strengths include standardized ECG procedures and 
carefully documented outcomes events ascertained by an independent adjudication 
committee.
In conclusion, in the ARIC study we showed that SMI is as common as CMI; 45% of the 
MIs are silent, and that both SMI and CMI are associated with poor outcomes. However, 
there are race and sex differences in the incidence and prognostic significance of SMI. Thus, 
accidental ECG finding of MI in persons without a history of MI may warrant enhanced 
CHD prevention efforts that take into account sex and race differences.
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This report from the Atherosclerosis Risk in Communities (ARIC) study, one of the 
largest community-based biracial cohort studies in the US, shows that presence of 
asymptomatic or silent myocardial infarction on screening electrocardiograms is a 
common finding; about 45% of the total number of myocardial infarctions in the study 
were silent. These silent myocardial infarctions were associated with increased risk of 
death in a magnitude that is relatively comparable to myocardial infarctions with clinical 
manifestations. However, race and sex differences in the incidence and prognostic 
significance of silent myocardial infarction were observed in this study. These findings 
highlights the importance of detection of silent myocardial infarctions, and the potential 
impact of such detection on personalized prevention of coronary heart disease that takes 
into account race and sex.
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Sex-race specific incidence rates (per 1000 person-years) of silent and clinical myocardial 
infarctions.
Zhang et al. Page 11














Coronary heart disease survival probability curves by myocardial infarction status.
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All-cause mortality survival probability curves by myocardial infarction status.
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Table 2





Incidence per 1000 person-years Events
N (%)
Incidence per 1000 person-years
All population (n=9,498) 317 (3.3) 3.84 (2.84–4.84) 386 (4.1) 4.68 (3.51–5.84)
 Men (n=4,098) 178 (4.3) 5.08 (3.34–6.82) 279 (6.8) 7.96 (5.64–10.3)
 Women (n=5,400) 139 (2.6) 2.93 (1.77–4.09) 107 (2.0) 2.25 (1.18–3.33)
 White (n=7,568) 243 (3.2) 3.69 (2.59–4.79) 332 (4.4) 5.04 (3.69–6.39)
 Black (n=1,930) 74 (3.8) 4.45 (2.05–6.84) 54 (2.8) 3.24 (1.13–5.36)
MI= myocardial infarction; SMI= Silent MI; CMI= MI with clinical manifestations.
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Table 3
Risk of Coronary Heart Disease Death Associated with Silent and Clinically Manifest Myocardial Infarction 
by Sex and Race.







 No MI (n=8,795) 0.7 1 (ref.) 1 (ref.)
 Silent MI (n=317) 3.2 4.10 (2.57–6.53) 3.06 (1.88–4.99)
 Clinical MI (n=386) 5.5 6.85 (4.78–9.79) 4.74 (3.26–6.90)
Men
0.089
 No MI (n=3,641) 1.0 1 (ref.) 1 (ref.)
 Silent MI (n=178) 3.6 3.23 (1.79–5.81) 2.77 (1.51–5.10)
 Clinical MI (n=279) 5.5 5.49 (3.61–8.34) 4.39 (2.83–6.63)
Women
 No MI (n=5,154) 0.4 1 (ref.) 1 (ref.)
 Silent MI (n=139) 2.8 6.92 (3.26–14.7) 3.79 (1.65–8.73)
 Clinical MI (n=107) 5.5 12.7 (6.66–24.0) 5.67 (2.78–11.6)
White
0.204
 No MI (n=6,993) 0.5 1 (ref.) 1 (ref.)
 Silent MI (n=243) 2.6 4.01 (2.23–7.24) 3.30 (1.82–6.01)
 Clinical MI (n=332) 4.6 6.60 (4.31–10.1) 4.52 (2.92–6.99)
Black
 No MI (n=1,802) 1.1 1 (ref.) 1 (ref.)
 Silent MI (n=74) 5.4 4.15 (1.93–8.89) 2.62 (1.06–6.48)
 Clinical MI (n=54) 11.5 7.22 (3.75–13.9) 5.57 (2.60–11.9)
HR=hazard ratio; CI=confidence interval; MI= myocardial infarction
*
Model 1 adjusted for age, sex, and race.
†
Model 2 adjusted for variables in model 1 plus study field center, body mass index, education, smoking status, systolic blood pressure, blood 
pressure lowering medications, diabetes mellitus, ratio of total cholesterol/high density lipoprotein, use of cholesterol lowering medications, use of 
aspirin, family history of coronary heart disease and serum creatinine (all at baseline).
††
Interactions tested in Model 2.
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Table 4
Risk of All-cause Mortality Associated with Different Patterns of Myocardial Infarction.







 No MI (n=8,795) 8.4 1 (ref.) 1 (ref.)
 Silent MI (n=317) 15.9 1.63 (1.33–1.99) 1.34 (1.09–1.65)
 Clinical MI (n=386) 18.7 1.85 (1.56–2.20) 1.55 (1.30–1.85)
Men
0.051
 No MI (n=3,641) 11.0 1 (ref.) 1 (ref.)
 Silent MI (n=178) 17.3 1.43 (1.11–1.85) 1.23 (0.94–1.60)
 Clinical MI (n=279) 18.7 1.65 (1.34–2.02) 1.45 (1.18–1.78)
Women
 No MI (n=5,154) 6.6 1 (ref.) 1 (ref.)
 Silent MI (n=139) 14.0 2.05 (1.49–2.81) 1.58 (1.13–2.20)
 Clinical MI (n=107) 18.9 2.59 (1.89–3.56) 1.83 (1.32–2.54)
White
0.178
 No MI (n=6,993) 8.0 1 (ref.) 1 (ref.)
 Silent MI (n=243) 14.6 1.50 (1.18–1.90) 1.31 (1.03–1.67)
 Clinical MI (n=332) 18.1 1.80 (1.49–2.17) 1.48 (1.22–1.79)
Black
 No MI (n=1,802) 9.8 1 (ref.) 1 (Ref.)
 Silent MI (n=74) 20.1 2.03 (1.40–2.96) 1.45 (0.96–2.21)
 Clinical MI (n=54) 23.0 2.14 (1.41–3.26) 1.97 (1.27–3.05)
HR=hazard ratio; CI=confidence interval; MI= myocardial infarction
*
Model 1 adjusted for age, sex, and race.
†
Model 2 adjusted for variables in model 1 plus study field center, body mass index, education, smoking status, systolic blood pressure, blood 
pressure lowering medications, diabetes mellitus, ratio of total cholesterol/high density lipoprotein, use of cholesterol lowering medications, use of 
aspirin, family history of coronary heart disease and serum creatinine (all at baseline).
††
Interactions tested in Model 2.
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